Goserelin in Early Breast Cancer Trials
Author Information
Author(s): M Kaufmann
Primary Institution: Department of Gynaecology and Obstetrics, Johann Wolfgang Goethe University, Frankfurt, Germany
Hypothesis
What is the safety and efficacy of goserelin compared to standard treatments in early breast cancer?
Conclusion
The ongoing trials will help define the role of goserelin in treating early breast cancer in premenopausal women.
Supporting Evidence
- The trials will include data from over 4000 patients treated with goserelin.
- Preliminary results are expected from the CRC trial in 1998 and from the ZEBRA and ECOG/SWOG trials in 1999.
- The trials aim to compare disease-free survival rates and overall survival rates between goserelin and standard treatments.
Takeaway
Doctors are testing a medicine called goserelin to see if it helps women with early breast cancer better than the usual treatments.
Methodology
The trials involve comparing goserelin with standard treatments like chemotherapy and tamoxifen in various patient groups.
Limitations
The results are still pending and depend on the number of disease recurrences.
Participant Demographics
Premenopausal and perimenopausal women, primarily under 50 years of age.
Want to read the original?
Access the complete publication on the publisher's website